Mifepristone oral form for its use in cervix ripening and labour induction
AssigneeNordic Group B.V.
InventorsSophie Rolande VAN TOMME, Helene Marie Virginie HERMAN, Hans SCHRAM
Life of this patent
Estimating the term…
Abstract
The invention relates to an oral dosage form of mifepristone of mifepristone oral formulation characterised in that said formulation comprises an amount selected from the group consisting of 75 mg, 150 mg or 300 mg mifepristone, and said formulation is for its use in the induction of labour and cervix ripening in a woman being at least 37 weeks pregnant.
Claims7
1-10. (canceled)
A method of inducing labor in a pregnant woman with at least 37 weeks gestation and an unfavorable cervix with a Bishop score of 0 to 6, the method comprising administering to the pregnant woman a mifepristone oral formulation comprising 300 mg of mifepristone, wherein the mifepristone oral formulation is administered in a single dose to the pregnant woman as an outpatient.
Dependencies are inferred from the claim text.